This is the reason why inhibition of DNA-dependent protein kinases (DNA-PKcs) involved in DDR and NHEJ pathways could be a new promising target in BRCA1-deficient breast cancer treatment [100,101]. This evidence concerns the gene BRCA1 and breast carcinoma.